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Lone Atrial Fibrillation
Does it Exist?
D. George Wyse, MD, PHD,* Isabelle C. Van Gelder, MD, PHD,y
Patrick T. Ellinor, MD, PHD,z Alan S. Go, MD,x Jonathan M. Kalman, MBBS, PHD,k
Sanjiv M. Narayan, MD, PHD,{ Stanley Nattel, MD,# Ulrich Schotten, PHD,**
Michiel Rienstra, MD, PHDy
Calgary, Alberta, and Montreal, Quebec, Canada; Groningen and Maastricht, the Netherlands;
Boston, Massachusetts; Oakland and San Diego, California; and Melbourne, AustraliaThe historical origin of the term “lone atrial ﬁbrillation” (AF) predates by
60 years our current understanding of the pathophysiology of AF, the multitude
of known etiologies for AF, and our ability to image and diagnose heart disease. The
term was meant to indicate AF in patients for whom subsequent investigations could
not demonstrate heart disease, but for many practitioners has become synonymous
with “idiopathic AF.” As the list of heart diseases has expanded and diagnostic
techniques have improved, the prevalence of lone AF has fallen. The legacy of the
intervening years is that deﬁnitions of lone AF in the literature are inconsistent so
that studies of lone AF are not comparable. Guidelines provide a vague deﬁnition
of lone AF but do not provide direction about how much or what kind of imaging
and other testing are necessary to exclude heart disease. There has been an
explosion in the understanding of the pathophysiology of AF in the last 20 years in
particular. Nevertheless, there are no apparently unique mechanisms for AF in
patients categorized as having lone AF. In addition, the term “lone AF” is not
invariably useful in making treatment decisions, and other tools for doing so have
been more thoroughly and carefully validated. It is, therefore, recommended that
use of the term “lone AF” be avoided.From
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1716diseases, as well as improved
methods of imaging and a clearer
understanding of pathophysi-
ology and genetics suggest thatConventional risk factors
Advancing age
Male
Coronary heart disease
Hypertension (above 140/90 mm Hg)
Heart failure
Valvular heart disease
Diabetes mellitus
Hyperthyroidism
Others
Less established risk factors
Chronic obstructive pulmonary disease
Left atrial dilation
Atrial conduction delay/PR interval
Left ventricular diastolic dysfunction
Left ventricular hypertrophy
Obesity
Obstructive sleep apnea syndrome
Genetic factors
Others
Emerging risk factors
Subclinical atherosclerosis
Borderline hypertension (between 120/80 mm Hg and 140/90 mm Hg)
Chronic kidney disease
Subclinical hyperthyroidism
Inﬂammation
Elevated natriuretic peptides
Widened pulse pressure
Excessive endurance exercise
Excessive alcohol intakeAF is rarely idiopathic (6,7).
This working group posits that the category of lone
(idiopathic) AF no longer has either mechanistic or clinical
utility, causes confusion in the literature because of tre-
mendous variability in its deﬁnitions, and should therefore
be avoided. Future directions in AF management and
research will be better served if AF is classiﬁed in a more
utilitarian and precise fashion, perhaps using terms that
assign both etiologic and mechanistic information when
appropriate. Unfortunately, our understanding of mecha-
nisms and etiology of AF remains incomplete at this time,
making such a classiﬁcation of AF an ongoing “work in pro-
gress.” Given these limitations, we believe that clinical risk
stratiﬁcation and decisions about therapy for AF are more
aptly done by specifying the nature and extent of underlying
heart disease and other concomitant diseases such as pul-
monary diseases, and by using schemes such as CHADS2
(congestive heart failure, hypertension, age 75 years, dia-
betes mellitus, stroke/systemic embolus), CHA2DS2VASc
(congestive heart failure, hypertension, age 75 years, dia-
betes mellitus, stroke/systemic embolus, vascular disease, age
65 to 74 years, female), or the ATRIA (Anticoagulation
Risk Factors In Atrial Fibrillation) study scoring system for
stroke risk and by the European Heart Rhythm Association
or Canadian Cardiovascular Society severity in atrial ﬁbril-
lation score for assessment of symptoms.
In the following sections, we will delineate the reasons for
recommending that this historical term be avoided.Increased height
Increased birth weight
Smoking
Caffeine intake
Ethnicity
Others
*The list is not necessarily exhaustive.Origin of Lone or Idiopathic AF
Historically, the term lone AF predates our current un-
derstanding of the multitude of disorders that likely
contribute to the initiation of AF and lead to changes in
the heart that could be considered heart disease. Although
others had previously noted AF in the absence of heart
disease, the term “lone AF” was coined 60 years ago in
1954 by Evans and Swann (8) to describe patients forJude Medical, Biosense Webster, and Boston
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013; revised manuscript received December 29,whom “subsequent investigation shows that heart disease is
absent.” It was, and still is, considered by many to be
synonymous with idiopathic AF. The term lone AF has
been widely used, and was generally accepted to comprise
a minority of AF cases, although in some reports, esti-
mates of approximately 30% were given (9). Over the
past 20 years, there has been an explosion of knowledge
about AF etiologies and mechanisms and new forms
of heart disease. The wide variety of conditions now
known to be associated with AF are listed in Table 1 (6,7).
The inclusion of some or all these factors and their
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1717resultant new heart disease forms has inﬂuenced the re-
ported proportion of patients with “lone or idiopathic” AF,
as is illustrated in Figure 1. Multiple scientiﬁc and technical
advances have been and continue to be made to identify
the mechanisms through which various etiologies lead to AF
(10). Although we currently cannot specify the pre-
cise mechanisms for AF in each patient, the goal of a
mechanistic classiﬁcation for AF is increasingly moving
from an inconceivable notion to a realistic scientiﬁc objec-
tive. At some point in the near future, we may be able to
classify an individual patient’s AF based, at least in part,
on mechanistic considerations. The majority of patients
without traditional heart disease likely have AF as a result
of multiple inﬂuences, rather than a single proximal “cause.”
These inﬂuences lead to structural changes in the heart
that have only recently been imaged or even conceptualized,
and could be considered new heart disease forms.Variation in the Deﬁnition of Lone AF
Current AF guidelines deﬁne lone AF as AF in younger
adults (age <60 years) with no clinical history or echo-
cardiographic evidence of concomitant cardiovascular orFigure 1
The Demise of Lone AF
The pie charts illustrate the approximate proportions of atrial ﬁbrillation (AF)
considered to be lone or idiopathic AF, that is, AF in the absence of apparent heart
disease in 1954 (upper left) and in 2014 (lower right). In the intervening years,
appreciation of a large and ever-expanding number of etiologic factors (center
block arrow) (Table 1) leading to an expanded deﬁnition of heart disease
detectable with modern imaging and testing (center boxed list) and subdividing
heart disease into traditional heart disease and new heart disease forms has
dramatically reduced lone or idiopathic AF from approximately 30% to
approximately 3%.pulmonary conditions or an acute trigger (11,12) Existing
guidelines do not specify which concomitant conditions
have to be excluded to classify AF as lone AF. This broad
deﬁnition has led to tremendous variation in what various
investigators have termed lone AF, leading to confusion
and diminishing the usefulness of the term. In Figure 2, we
depict some of the common conditions associated with AF
and the extent to which they were excluded (or not) in 125
published reports on lone AF in the literature (http://www.
ncbi.nlm.nih.gov/pubmed; search criteria were “lone atrial
ﬁbrillation” and “idiopathic atrial ﬁbrillation,” both as text
terms and as MESH terms). Imprecision is further
increased because exclusion is sometimes based on retro-
spectively applied International Classiﬁcation of Diseases,
tenth revision, codes rather than prospective evaluation of
individual patients. For example, the risk factor most often
excluded in the literature is “signiﬁcant” coronary heart
disease (excluded in 69% of the studies). However, even in
those studies, there was not a consistent deﬁnition for sig-
niﬁcant coronary heart disease, most studies did not provide
information on the extent of diagnostic testing to rule out
this condition, and the same degree of testing was not
applied in all patients. Similar variability appears in the age
criteria for lone AF, with only 23% of the studies excluding
patients age >60 years. The selection of an age threshold of
60 years appears arbitrary, and is not based on any clear
pathophysiological justiﬁcation.Figure 2
Variation in the Deﬁnition of Lone AF
Survey of 125 studies reporting on lone atrial ﬁbrillation (AF) indicating the
proportion of studies that excluded various risk factors for AF. The vertical axis is
the percentage of studies and the bars represent the proportion that excluded a
particular risk factor. COPD ¼ chronic obstructive pulmonary disease.
Figure 3
Time-Dependent Atrial Remodeling and
Development of AF
A hypothetic construct over time indicating the interrelationships between time,
risk factors for atrial ﬁbrillation (AF), atrial remodeling, detection of risk factors for
atrial remodeling, and progression from sinus rhythm (SR) through paroxysmal,
persistent and permanent AF. ECV ¼ electrical cardioversion. (Adapted from Cosio
FG, Aliot E, Botto GL, et al. Delayed rhythm control of atrial ﬁbrillation may be a
cause of failure to prevent recurrences: reasons for change to active
antiarrhythmic treatment at the time of the ﬁrst detected episode. Europace
2008;10:21–7 [104], by permission of Oxford University Press.).
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1718Although only echocardiography is speciﬁcally mentioned
in guideline deﬁnitions, next to patient history and physical
examination, the most used diagnostic tests in the literature
for exclusion of concomitant diseases were a 12-lead elec-
trocardiogram, transthoracic echocardiography, and selected
laboratory testing for thyroid dysfunction, diabetes mellitus,
C-reactive protein, and white blood cell count when an
infection was suspected. The majority of studies describe
that stress testing was only performed if coronary heart
disease was clinically suspected. Left ventricular diastolic
function measurements were only performed in recent years,
and cardiac magnetic resonance imaging or other types of
assessment for new heart disease forms not at all.
Another factor to be considered is that the development
of underlying heart disease is often a continuous process
over time. Although heart disease is recognized earlier since
(noninvasive) diagnostic tests have improved, it may mani-
fest as AF before it can be reliably detected using currently
available tests (13,14). The concept of progressive (atrial)
remodeling has been around for some time and is depicted
hypothetically in Figure 3. It, therefore, remains uncertain
whether lone AF really is AF without heart disease, or in
some cases is AF with heart disease that is currently below
the threshold for detection.
Given these diverse considerations and limitations in the
ability of currently available diagnostic testing modalities to
reliably rule out all heart disease, the diagnosis of lone AF
has limited clinical utility.Reported Prevalence of Lone AF
The reported prevalence of lone AF varies widely, ranging
from 0.2% to 68% depending on the deﬁnition of lone AF,
the population studied (Fig. 2), and diagnostic tools used
(15,16). The Framingham Heart Study reported a lone AF
prevalence of 11%, using a lenient deﬁnition of hypertension
by modern standards (>160/95 mm Hg) without echocar-
diographic assessment. In the Olmsted County cohort, the
prevalence of lone AF ranged from 2% to 4%, using different
age cut-off values, and additional chart review (15,17,18).
More recent reports of the AFNET (German Competence
Network on Atrial Fibrillation) study, Euro Heart Survey,
and REALISE-AF (Real-Life Global Survey Evaluating
Patients With Atrial Fibrillation) registries report lone AF
prevalence of, respectively, 12%, 10%, and 5% (19–21).
Using a more stringent deﬁnition of lone AF in the Euro
Heart Survey, the prevalence of lone AF fell to 3% (22). In
hospital-based studies, the prevalence of lone AF varies from
2% to 45%, depending again on the patient characteristics
included (23–26). It appears that a larger proportion of
patients with paroxysmal AF is diagnosed with lone AFcompared to patients in permanent AF, among whom the
proportion of lone AF is relatively low (27).Contemporary Imaging and Lone AF
Beyond the obvious exclusion of valvular pathology, coro-
nary artery disease, and measures of left ventricular size and
function, in 2014, the extensiveness of baseline imaging
requirement and the interval at which imaging should be
repeated to exclude heart disease has not been speciﬁed or
widely accepted. The considerations in enumerating a
minimal imaging set are numerous.
The question of whether isolated left atrial enlargement
represents heart disease is particularly challenging. As others
have observed (28), left atrial enlargement may be either a
cause or a consequence of AF. Importantly, left atrial
enlargement is a well-described risk marker for cardiac
events in patients with and without AF (29,30). The most
accurate and best technique to detect structural and func-
tional change in the left atrium remains in evolution (31).
Perhaps one of the simplest is measurement of P-wave
duration. Both M-mode and 2-dimensional echocardiogra-
phy are established methods to quantify left atrial size and
volume. Do 3-dimensional echocardiography imaging or
magnetic resonance imaging add to this assessment? An
JACC Vol. 63, No. 17, 2014 Wyse et al.
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1719M-mode analysis of left atrial diameter may not accurately
reﬂect the size of the left atrium because of its asymmetric
shape and the nonuniformity of atrial enlargement (31,32).
In contrast, left atrial volume index has been shown to
provide a more accurate assessment when compared with
gold-standard imaging techniques such as magnetic reso-
nance imaging, and may correlate best with cardiovascular
risk (29).
Another recent innovation in echocardiographic evalua-
tion of the atrium is the use of 2-dimensional speckle
tracking echocardiography to measure the deformation of
atrial myocardium measured as strain or strain rate. In
addition, a number of studies have demonstrated a rela-
tionship between left atrial strain and the extent of atrial
remodeling and atrial myocardial ﬁbrosis (33).
Magnetic resonance imaging is considered the gold
standard for assessment of left atrial volume because of its
high spatial resolution, but is less practical than transthoracic
echocardiography as a routine test in AF patients (34,35). In
recent years, late gadolinium enhancement magnetic reso-
nance imaging has been identiﬁed as a tool to determine
the extent of atrial ﬁbrosis in AF (36,37). Although these
results are in the early stages of being reproduced, the ability
to identify early degrees of atrial structural change would no
doubt impact upon the presence or absence of heart disease.
While it is widely agreed that the presence of ventricular
systolic dysfunction excludes a diagnosis of lone AF, the
impact of ventricular diastolic dysfunction has generally not
been considered in this context. Nevertheless, considerable
data suggest that hypertension, left ventricular hypertrophy,
ventricular diastolic dysfunction, atrial enlargement, and AF
may form a pathophysiologic continuum (38,39). Ventricular
diastolic dysfunction coexists with other AF risk factors
including age, obesity, and diabetes mellitus, but nevertheless
confers independent AF risk, and there is no reason it should
not be considered heart disease. Clinical studies report that
AF is associated with an impaired prognosis in heart failure
patients with reduced or preserved left ventricular function
(40–43). Right ventricular dysfunction in chronic obstructive
pulmonary disease and other noncardiac causes of pulmonary
hypertension should also not be ignored.Genetics and Lone AF
The heritability of AF has been well established in studies
from Framingham (44,45), Iceland (46), and Denmark (47).
Having an affected family member is associated with a 40%
increased risk of AF (45), and the heritability of AF appears
to be greater among persons with lone or early-onset AF
(44–46). Both rare and common variants related to AF
have been identiﬁed. Genomewide association studies haveidentiﬁed at least 10 distinct loci with common variants
related to AF (48–52). With this background in mind, it is
interesting that there is considerable overlap in the common
genetic predisposition between early-onset AF (52) and
more typical forms of AF observed in the community (50).
Persons with lone AF have frequently been reported to have
mutations in a range of cardiac ion channels, structural
proteins, and signaling molecules with nearly 20 AF-related
genes identiﬁed to date. It is currently unclear how many
patients would continue to be classiﬁed as having lone AF
after accounting for the impact of the mutations related to
AF itself.
Pathophysiological Mechanisms
and Lone AF
From a pathophysiological perspective, the term lone AF
might be reserved for AF in the absence of any known
cardiac pathophysiological conditions. The pathophysiolo-
gist is interested in lone AF largely because of the oppor-
tunity to identify AF mechanisms independently from
known contributors. Mechanistic studies in animal models
have provided insights into explaining how risk factors can
facilitate induction and perpetuation of AF. Thus far, there
are no unique mechanisms found in lone AF.
Clinical AF results from an interaction between triggers
(53) and sustaining mechanisms (“substrates”) composed of
electrical (54) and/or structural components (55). Atrial
ﬁbrillation is often triggered by ectopy from the pulmonary
veins (53) or less deﬁned atrial sites (56–58). Pulmonary vein
triggers may be promoted by activity from nearby gangli-
onated plexi (59,60), and relate to structural-functional ab-
normalities at the junction between left atrial and pulmonary
vein tissue (61). Similar mechanisms likely initiate AF in
diverse populations (62,63), as evidenced by the success of
pulmonary vein isolation in patients with (64,65) and with-
out (63) traditional risk factors. Mechanistically, extensive
AF ablation lesions may also modify AF sustaining sources
(66) or autonomic ganglia (60). The AF-sustaining mecha-
nisms are facilitated by electrical (67) and structural (68)
remodeling in both AF patients with and without (69–72)
cardiac comorbidity.
Two potential sustaining mechanisms have been recog-
nized: ﬁrst, by spatially localized sources (or drivers) in the
form of electrical rotors (spiral waves) or, second, by non-
localized spatially meandering mechanisms including mul-
tiwavelet reentry (73). The concept of “one true mechanism”
is clearly untenable, and in any case, stable AF sources
(74,75) and multiwavelet reentry (55,76) have both been
reported in diverse patients with a wide range of ventricular
function, comorbidities, and ages (77). In the CONFIRM
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Without Focal Impulse and Rotor Modulation) trial (74),
wide-area computational mapping revealed 2 to 3 sources
per patient in right or left atria. Localized sources have
been reported by several groups in patients both with
lone AF and with cardiac diseases including heart failure
(74,75,78–80). Other detailed mapping studies suggest that
stable sources are much less common (81), and that both
the number and complexity of sources increase with AF
duration (74,81,82).
Chronic atrial stretch, as a result of AF and several con-
ditions associated with AF, leads to the activation of
numerous proﬁbrotic and hypertrophic signaling pathways,
resulting in ﬁbroblast proliferation and differentiation into
myoﬁbroblasts and collagen synthesis (83–87). The accu-
mulation of collagen ﬁbers in the extracellular matrix causes
progressive loss of electrical coupling between muscle bun-
dles (82,88,89). The resulting conduction abnormalities lead
to reentry, conduction block, and/or electrical dissociation
(90,91). Similarly, inﬂammatory alterations likely play an
important role in the development of the AF substrate and
may be associated with recurrences of AF (92). In 1 study
of lone AF patients, localized lymphomononuclear inﬁl-
trates and ﬁbrosis were the most common pathological al-
terations in atrial biopsies (93). Myocarditis may promote
AF by shortening refractoriness, slowing conduction (94),
and via oxidative injury, contribute to atrial myocyte apo-
ptosis and remodeling (95). Another remodeling component
that leads to AF-promoting conduction disturbances is
changes in connexins, intercellular gap-junction hemi-
channels that mediate cell-to-cell electrical coupling, which
may be down-regulated and/or spatially redistributed in AF
patients (96,97).
Prognosis and Treatment of Lone AF
Studies concerning prognosis of lone AF report contradictory
results, likely as the result of the heterogeneity in deﬁnitions of
lone AF, comorbidities, study populations, and duration of
follow-up. The prognosis of AF is primarily, but not always,
determined by its cardiac and associated comorbidities (98).
Epidemiological studies show that AF may have a benign
prognosis until traditional cardiovascular risk factors arise in
follow-up (99–101). As in other patient populations, hyper-
tension, diabetes, and other factors confer risk for stroke,
systemic embolism, heart failure, and mortality (102,103), as
do a wide array of additional pathophysiological elements that
may be difﬁcult to identify. With respect to treatment, the
presence of stroke risk factors as manifest in CHADS2 and
CHA2DS2-VASc scores and the risk of bleeding as manifest
in ATRIA, HEMORRHAGES (hepatic or renal disease,
ethanol abuse, malignancy, older age, reduced platelet countor function, rebleeding, hypertension, anemia, genetic factors,
excessive fall risk, stroke), and HAS-BLED (hypertension,
abnormal renal/liver function, stroke, bleeding history or
predisposition, labile international normalized ratio, elderly,
drugs/alcohol) scores have been more effective at guiding
therapy for stroke prevention, while the European Heart
Rhythm Association or Canadian Cardiovascular Society
Severity in Atrial Fibrillation symptom scores have beenmore
effective at guiding rhythm management than the arbitrary
designation of AF without detected heart disease.
Conclusions and Recommendations
A consideration of our current state of knowledge about AF
and the inconsistency in usage of the term leads to the
logical proposal that the historical term lone AF should be
avoided. A thorough search for risk factors and cardiovas-
cular disease is recommended. Future studies should inves-
tigate whether optimal treatment of these risk factors may
prevent or delay the development of AF, improve mainte-
nance of sinus rhythm, and ultimately improve prognosis
once AF appears.
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